keyword
MENU ▼
Read by QxMD icon Read
search

"metastatic breast cancer"

keyword
https://www.readbyqxmd.com/read/29340882/circulating-small-sized-endothelial-microparticles-as-predictors-of-clinical-outcome-after-chemotherapy-for-breast-cancer-an-exploratory-analysis
#1
Elisa García Garre, Ginés Luengo Gil, Silvia Montoro García, Enrique Gonzalez Billalabeitia, Marta Zafra Poves, Elena García Martinez, Vanessa Roldán Schilling, Esther Navarro Manzano, Alejandra Ivars Rubio, Gregory Y H Lip, Francisco Ayala de la Peña
PURPOSE: Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer. METHODS: We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340881/circulating-free-dna-integrity-and-concentration-as-independent-prognostic-markers-in-metastatic-breast-cancer
#2
Jie Cheng, Tim Holland-Letz, Markus Wallwiener, Harald Surowy, Katarina Cuk, Sarah Schott, Andreas Trumpp, Klaus Pantel, Christof Sohn, Andreas Schneeweiss, Barbara Burwinkel
PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis. METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340880/gata-3-is-superior-to-gcdfp-15-and-mammaglobin-to-identify-primary-and-metastatic-breast-cancer
#3
Yun-Bi Ni, Julia Y S Tsang, Mu-Min Shao, Siu-Ki Chan, Sai-Yin Cheung, Joanna Tong, Ka-Fai To, Gary M Tse
PURPOSE: Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear. METHODS: To address these questions, totally 993 invasive breast cancers (IBC), 254 paired nodal metastases, 23 distant metastases, and 208 lung carcinomas were included. GATA-3 expression was analyzed by immunohistochemistry and compared to other breast markers [gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MGB)]...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29339542/ampk-akt-double-negative-feedback-loop-in-breast-cancer-cells-regulates-their-adaptation-to-matrix-deprivation
#4
Manipa Saha, Saurav Kumar, Shoiab Bukhari, Sai A Balaji, Prashant Kumar, Sravanth K Hindupur, Annapoorni Rangarajan
Cell detachment from the extracellular matrix triggers anoikis. Disseminated tumor cells must adapt to survive matrix deprivation, while still retaining the ability to attach at secondary sites and re-initiate cell division. In this study, we illuminate mechanisms that enable reversible matrix attachment by breast cancer cells. Matrix deprival triggered AMPK activity and concomitantly inhibited AKT activity by upregulating the AKT phosphatase PHLPP2. The resultant pAMPKhigh/pAKTlow state was critical for cell survival in suspension, as PHLPP2 silencing also increased anoikis while impairing autophagy and metastasis...
January 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29339084/mir-613-inhibits-cell-migration-and-invasion-by-downregulating-daam1-in-triple-negative-breast-cancer
#5
Huaping Xiong, Ting Yan, Weijie Zhang, Fangfang Shi, Xuesong Jiang, Xiaohua Wang, Shoushan Li, Ying Chen, Cheng Chen, Yichao Zhu
Dishevelled-associated activator of morphogenesis 1 (Daam1) is a formin protein and participates in regulating cell migration of triple-negative breast cancer (TNBC) cells. The specific miRNA targeting Daam1 and mediating cell migration and invasion remains obscure. This experiment investigated the suppressive role of miR-613 in TNBC cells. The luciferase activity of Daam1 3'-untranslated region (3'-UTR) based reporters constructed in HEK-293T and MCF-7 cells suggested that Daam1 was the target gene of miR-613...
January 12, 2018: Cellular Signalling
https://www.readbyqxmd.com/read/29338448/the-safety-of-palbociclib-for-the-treatment-of-advanced-breast-cancer
#6
Tom Degenhardt, Rachel Wuerstlein, Tanja Eggersmann, Nadia Harbeck
Despite improvements in the diagnosis and management of early stage breast cancer, about one third of the patients still progress to metastatic disease. Most of the patients with metastatic breast cancer have a hormone receptor positive and human epidermal growth factor receptor 2 negative subtype with a median survival of more than 3 years. For these patients, endocrine therapy with its favorable toxicity profile is the current standard of care. However, patients with metastatic breast cancer have an incurable disease...
January 17, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29337111/early-re-staging-and-molecular-subtype-shift-surveillance-of-locally-recurrent-or-metastatic-breast-cancer-a-new-pet-ct-integrated-precise-algorithm
#7
Wei Guo, Bing Hao, Nana Luo, Dan Ruan, Xiuyu Guo, Hao-Jun Chen, Hua Wu, Long Sun
Recurrent breast cancer poses considerable diagnostic and therapeutic challenges for clinic. Clinical suspicion of recurrence must be first confirmed by imaging studies. Then re-biopsy of suspected recurrence and metastasis in patients with breast cancer is recommended in the practice guidelines of the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) to confirm whether the molecular subtype changes. It may change the individual treatment plan directly. Our research provided an integrated algorithm for locally recurrent or distant metastatic breast cancer, including early relapse detection and subsequently a new practical PET/CT imaging guide biopsy approach for surveilling molecular subtype shifts of the recurrent breast cancer...
January 11, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29336662/body-mass-index-in-her2-negative-metastatic-breast-cancer-treated-with-first-line-paclitaxel-and-bevacizumab
#8
Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Luigi Di Lauro, Marco Mazzotta, Claudio Botti, Fiorentino Izzo, Luca Marchetti, Silverio Tomao, Paolo Marchetti, Clara Natoli, Antonino Grassadonia, Teresa Gamucci, Lucia Mentuccia, Emanuela Magnolfi, Angela Vaccaro, Alessandra Cassano, Ernesto Rossi, Andrea Botticelli, Valentina Sini, Maria G Sarobba, Maria Agnese Fabbri, Luca Moscetti, Antonio Astone, Andrea Michelotti, Claudia De Angelis, Ilaria Bertolini, Francesco Angelini, Gennaro Ciliberto, Marcello Maugeri-Saccà, Antonio Giordano, Maddalena Barba, Patrizia Vici
The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype...
January 16, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29336185/an-update-on-first-line-therapies-for-metastatic-breast-cancer
#9
Palma Fedele, Mariangela Ciccarese, Giammarco Surico, Saverio Cinieri
In recent years, outcomes of patients with metastatic breast cancer (MBC) have improved due to a greater understanding of the mechanisms of carcinogenesis in the development of newer molecularly targeted drugs, especially those as a front-line therapy. Remarkable improvements have been made in the treatment of hormone receptor positive (HR+) and Her2 positive MBC and currently targeted treatment strategies represent a valid first line treatment. Areas covered: Herein, the authors provide an overview of the first-line pharmacotherapies currently available for the treatment of MBC and provide their expert perspectives on the area...
January 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29334609/score-for-the-survival-probability-in-metastasis-breast-cancer-a-nomogram-based-risk-assessment-model
#10
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Purpose: Survival of metastatic breast cancer patient remains unknown and varies greatly from person to person. Thus, we aimed to construct a nomogram to quantify the survival probability of patients with metastatic breast cancer (MBC). Materials and methods: We had included 793 MBC patients and calculated trends of case fatality rate by Kaplan-Meier method and joinpoint regression. 634 patients with MBC between January 2004 and July 2011 and 159 patients with MBC between August 2011 and July 2013 were assigned to training cohort and internal validation cohort, respectively...
January 2, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29333945/remarkable-response-with-pembrolizumab-plus-albumin-bound-paclitaxel-in-2-cases-of-her2-positive-metastatic-breast-cancer-who-have-failed-to-multi-anti-her2-targeted-therapy
#11
Bian Li, Wang Tao, Zhang Shao-Hua, Q U Ze-Rui, Jin Fu-Quan, L I Fan, Jiang Ze-Fei
In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab,lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients.Two patients with metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy were treated with pembrolizumab(2mg/Kg, day1) plus albumin-bound paclitaxel(125mg/m2, day1,8) every 3 weeks.CT evaluation and HER2 ECD test were performed every 2 cycles...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29332137/variation-in-guideline-concordant-care-for-elderly-patients-with-metastatic-breast-cancer-in-the-united-states
#12
Philip D Poorvu, Ines Vaz-Luis, Rachel A Freedman, Nancy U Lin, William T Barry, Eric P Winer, Michael J Hassett
PURPOSE: Prior studies have identified shortcomings in the quality of care for early-stage breast cancer. Guidelines recommend systemic therapy for metastatic breast cancer (MBC), but few studies have examined guideline concordance for these patients. METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify patients aged ≥ 66 diagnosed in 2010-2011 with de novo MBC who were continuously enrolled in fee-for-service Medicare...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29329582/when-do-patient-reported-quality-of-life-indicators-become-prognostic-in-breast-cancer
#13
Chee Khoon Lee, Malcolm Hudson, John Simes, Karin Ribi, Jürg Bernhard, Alan S Coates
BACKGROUND: Various patient reported quality-of-life indicators are independently prognostic for survival in metastatic breast cancer and other cancers. The same measures recorded at first diagnosis of early breast cancer carry no corresponding prognostic information. The present study aims to assess at what time in the disease evolution the prognostic association appears. METHODS: Among 8024 patients enrolled in one of seven randomized controlled trials in early-stage breast cancer 3247 had a breast cancer relapse after a median follow-up of 12...
January 12, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29329006/ongoing-unmet-needs-in-treating-estrogen-receptor-positive-her2-negative-metastatic-breast-cancer
#14
REVIEW
Gül A Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada
Estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) is the most common MBC subtype and currently remains incurable, with a median overall survival of 24.8 months (95% confidence interval, 21.3-30.3). Common sites of metastases are bone, viscera, and brain, causing significant symptoms that negatively affect patient functioning, quality of life (QoL), and work productivity. Guidelines state that endocrine therapy (ET) is preferable to chemotherapy as first-line treatment for patients with ER+ MBC, regardless of limited visceral metastases, unless rapid tumor response is required or ET resistance is suspected...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29328377/feature-genes-in-metastatic-breast-cancer-identified-by-metade-and-svm-classifier-methods
#15
Youlin Tuo, Ning An, Ming Zhang
The aim of the present study was to investigate the feature genes in metastatic breast cancer samples. A total of 5 expression profiles of metastatic breast cancer samples were downloaded from the Gene Expression Omnibus database, which were then analyzed using the MetaQC and MetaDE packages in R language. The feature genes between metastasis and non‑metastasis samples were screened under the threshold of P<0.05. Based on the protein‑protein interactions (PPIs) in the Biological General Repository for Interaction Datasets, Human Protein Reference Database and Biomolecular Interaction Network Database, the PPI network of the feature genes was constructed...
January 9, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29327085/acceptance-and-commitment-therapy-for-symptom-interference-in-metastatic-breast-cancer-patients-a-pilot-randomized-trial
#16
Catherine E Mosher, Ekin Secinti, Ruohong Li, Adam T Hirsh, Jonathan Bricker, Kathy D Miller, Bryan Schneider, Anna Maria Storniolo, Lida Mina, Erin V Newton, Victoria L Champion, Shelley A Johns
PURPOSE: Breast cancer is the leading cause of cancer mortality in women worldwide. With medical advances, metastatic breast cancer (MBC) patients often live for years with many symptoms that interfere with activities. However, there is a paucity of efficacious interventions to address symptom-related suffering and functional interference. Thus, this study examined the feasibility and preliminary efficacy of telephone-based acceptance and commitment therapy (ACT) for symptom interference with functioning in MBC patients...
January 12, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29324303/first-line-vs-second-line-fulvestrant-for-hormone-receptor-positive-advanced-breast-cancer-a-post-hoc-analysis-of-the-confirm-study
#17
Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, Jasmine Lichfield, Miguel Martin
OBJECTIVES: The double-blind, phase III CONFIRM study (NCT00099437) evaluated fulvestrant 500 mg vs fulvestrant 250 mg in postmenopausal women with hormone receptor-positive locally advanced/metastatic breast cancer (LA/MBC). This post-hoc analysis investigated the efficacy and safety of fulvestrant given either first-line or second-line for advanced disease. MATERIALS & METHODS: Progression-free survival (PFS) and overall survival (OS) with fulvestrant 500 mg vs fulvestrant 250 mg was evaluated using unadjusted log-rank tests in patients treated in the first- (progression during or within 12 months after completing adjuvant endocrine therapy; n = 387) and second-line (following endocrine therapy for LA/MBC; n = 343) settings...
January 8, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29322113/a-systematic-review-and-pooled-analysis-of-studies-of-oral-etoposide-in-metastatic-breast-cancer
#18
Ioannis A Voutsadakis
Objective: Oral etoposide has been used as a later line therapy for metastatic breast cancer for more than twenty years. Its efficacy and clinical usefulness has been suggested in small phase II studies in the metastatic breast cancer population and the drug has also the added advantage of convenient oral administration. Despite these advantages, the place of oral etoposide in treatment of metastatic breast cancer has been challenged in the last decade due to introduction of several other chemotherapeutics, including options available orally, as well as novel targeted therapies...
January 2018: European Journal of Breast Health
https://www.readbyqxmd.com/read/29321615/functional-isolation-of-tumor-initiating-cells-using-microfluidic-based-migration-identifies-phosphatidylserine-decarboxylase-as-a-key-regulator
#19
Yu-Chih Chen, Brock Humphries, Riley Brien, Anne E Gibbons, Yu-Ting Chen, Tonela Qyli, Henry R Haley, Matthew E Pirone, Benjamin Chiang, Annie Xiao, Yu-Heng Cheng, Yi Luan, Zhixiong Zhang, Jason Cong, Kathryn E Luker, Gary D Luker, Euisik Yoon
Isolation of tumor-initiating cells currently relies on markers that do not reflect essential biologic functions of these cells. We proposed to overcome this limitation by isolating tumor-initiating cells based on enhanced migration, a function tightly linked to tumor-initiating potential through epithelial-to-mesenchymal transition (EMT). We developed a high-throughput microfluidic migration platform with automated cell tracking software and facile recovery of cells for downstream functional and genetic analyses...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29315431/receptor-conversion-in-distant-breast-cancer-metastases-a-systematic-review-and-meta-analysis
#20
Willemijne A M E Schrijver, Karijn P M Suijkerbuijk, Carla H van Gils, Elsken van der Wall, Cathy B Moelans, Paul J van Diest
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated. Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases...
January 5, 2018: Journal of the National Cancer Institute
keyword
keyword
22087
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"